Listing Title
Listing Category
Description
A phase 3, open-label, randomized study to assess the efficacy and safety of Camizestrant (AZD9833), a next generation. Oral selective estrogen receptor degrader, versus standard endocrine therapy, as adjusted treatment for patients with ER+/HER2- early breast cancer and an intermediate -high or high risk of recurrence who have completed definitive locoregional treatment and have no evidence or disease
Study Status
Active: Open to Patient Enrollment
Trial Documentation:
Principal Investigator
Dr. Robert Schumaker, Tennessee Cancer Specialists
Listing Title
Listing Category
Description
A single-arm, open-label, Phase 2 study evaluating A single-arm, open-label, Phase 2 study evaluating by an On Body Delivery System, in combination with weekly carfilzomib and dexamethasone in adult participants with relapsed and/or refractory multiple myeloma (RRMM)
Study Status
Active: Open to Patient Enrollment
Trial Documentation:
Principal Investigator
Dr. Saji Eapen, Tennessee Cancer Specialists